CHOlesterol Personalized INnovation (CHOPIN) : improves treatment for hypercholesterolemia
The CHOPIN (CHolesterol Personalized INnovation) project is a large-scale translational research project which won the « Recherche Hospitalo-Universitaire en santé » call for projects under the second wave of the «Investissements d’Avenir».
Led by the Département Hospitalo-Universitaire 2020 – DHU 2020, and coordinated by Professor Bertrand Cariou, director of the thorax institute at CHU de Nantes Hospital, this project is aimed at ensuring personalised treatment for familial hypercholesterolemia, a major public health issue.
As things stand, statins are the first line treatment for familial hypercholesterolemia. However, these do not always reach the therapeutic target, especially in patients at high risk of a heart attack or stroke. The research and development of new therapeutic molecules is therefore required.
CHOPIN’s objectives are therefore to identify new cardiovascular risk markers and new targets for the metabolism of LDL-cholesterol, a molecule which plays a key role in the development and progression of cardiovascular disease.
The CHU de Nantes-based team brings together 14 academic and industry partners, who are specialists in dyslipidemia. Thanks to this, CHOPIN will allow for the identification of the patients at greatest risk of developing these conditions, and offer them the best therapeutic strategies and most innovative forms of treatment, with a view to improving their prognosis and quality of life.
CHOPIN is a patient-focused project which is also backed by the French familial hypercholesterolemia network and by the Nouvelle Société Francophone d’Athérosclérose (NSFA – New French Society of Atherosclerosis), with support from patients associations including Anhet-F.